Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in leydig cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 53 | 0.91 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
Knock down and overexpress PLPP3 in astrocytes; measure glucocerebrosidase (GCase) activity and LC3-II and p62 flux and α-synuclein uptake and degradation, and dopamine neuron survival in co-culture.
- Cell type
- astrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- glucocerebrosidase (GCase) activity and LC3-II and p62 flux
- Functional readout
- α-synuclein uptake and degradation, and dopamine neuron survival in co-culture
- Rule-out
- If neither arm moves glucocerebrosidase (GCase) activity by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PLPP3 in iPSC-derived midbrain astrocytes; n = 3 differentiations; readouts: glucocerebrosidase (GCase) activity and LC3-II and p62 flux; α-synuclein uptake and degradation, and dopamine neuron survival in co-culture. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PLPP3 in astrocytes, braak-0.65 (p 0.058) → +0.31 (p 0.414)receipt 6802
- PLPP3 in dopamine neurons, braak+0.02 (p 0.964) → +0.05 (p 0.893)receipt 6803
Swarm cases
receipt 6803: PLPP3 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.800, n 18), 95% CI -0.52 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.874, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.827, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.06, sign flips 4; without severely affected donors -0.06 (p 0.800, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLPP3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 6802: PLPP3 in astrocytes, braak
- power
- full sample -0.02 (p 0.928, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.908, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.09, sign flips 7; without severely affected donors -0.02 (p 0.928, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLPP3 in astrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts